Fig. 4: Hypoxia-induced miR-210-3p inhibits BARD1/BRCA1 signalling to avoid cell cycle arrest in hypoxia.

a qRT-PCR assay of BARD1 mRNA expression in endometrial stromal cells (ESCs) (left panel) and Ishikawa cells (right panel) infected with LV-In-CN or LV-In-210 under normoxia or hypoxia. The bars show the mean value of three independent experiments ± standard deviation. *P < 0.05 versus LV-In-CN (Normoxia); ^#P < 0.05 versus LV-In-CN (Hypoxia) (n = 5 for ESCs, paired Studentʼs t-test). b Western blot of BARD1, BRCA1 and HIF-1α protein levels in ESCs (left panel) and Ishikawa cells (right panel) infected with LV-In-CN or LV-In-210 under normoxia or hypoxia (n = 5 for ESCs). β-Actin served as the internal control. c Western blot assay of BARD1 and BRCA1 protein levels in ESCs (upper panel) and Ishikawa cells (lower panel) infected with LV-CN, LV-210 or LV-BARD1 under normoxia. d Cell cycle distribution of LV-BARD1 or negative control (LV-CN) treated ESCs (left panel, n = 5) or Ishikawa cells (right panel) under hypoxia. Each value represents the mean ± standard deviation of three independent experiments. d Western blot of BARD1, BRCA1, p-BRCA1, p53, p21, Cdc2, cyclin B1 and HIF-1α protein levels in ESCs (left panel, n = 5) and Ishikawa cells (right panel) infected with LV-BARD1 or its negative control (LV-CN) under hypoxia. e Cell cycle distribution of LV-In-CN, LV-In-210 or LV-In-210 plus LV-In-BARD1 treated ESCs (upper panel, n = 5) or Ishikawa cells (lower panel) under hypoxia. Each value represents the mean ± standard deviation of three independent experiments. f Western blot of BARD1, BRCA1, p-BRCA1, p53, p21, Cdc2, cyclin B1 and HIF-1α protein levels in ESCs and Ishikawa cells infected with LV-In-CN, LV-In-210 or LV-In-210 plus LV-In-BARD1 under hypoxia